Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis
Early Phase 1
Completed
- Conditions
- Uveitis
- Interventions
- Drug: Norflo OroDrug: Placebo for Norflo Oro
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Eye Pharma
- Target Recruit Count
- 49
- Registration Number
- NCT03584724
- Locations
- 🇺🇸
Bascom Palmer Eye Institute, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath